{"transactions":[{"id":1488733,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T22:45:54.000Z","date":"2024-06-05","kind":"sale","planned":false,"acquired":false,"shares":150000,"price":4.24,"value":636000.0,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.10 to $4.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC (\"AE7\"), and a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":5855077,"source":{"system":"sec-edgar","filing":"0001035443-24-000171","document":"wk-form4_1717713946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544324000171/wk-form4_1717713946.xml","form_type":"4"}},{"id":1488732,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T22:45:54.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":150000,"price":4.21,"value":631500.0,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.12 to $4.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC (\"AE7\"), and a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":6005077,"source":{"system":"sec-edgar","filing":"0001035443-24-000171","document":"wk-form4_1717713946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544324000171/wk-form4_1717713946.xml","form_type":"4"}},{"id":1725803,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":2,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":3,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T23:53:29.000Z","date":"2023-11-29","kind":"other","planned":false,"acquired":false,"shares":575000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC, (\"AE7\") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC, (\"AE7\") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by AE7, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":203977,"source":{"system":"sec-edgar","filing":"0001035443-23-000327","document":"wk-form4_1701474795.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000327/wk-form4_1701474795.xml","form_type":"4"}},{"id":1725802,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":2,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":3,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T23:53:29.000Z","date":"2023-11-29","kind":"other","planned":false,"acquired":true,"shares":575000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC, (\"AE7\") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC, (\"AE7\") a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by AVI, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":6155077,"source":{"system":"sec-edgar","filing":"0001035443-23-000327","document":"wk-form4_1701474795.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000327/wk-form4_1701474795.xml","form_type":"4"}},{"id":1748885,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":2,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":3,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-06T21:56:09.000Z","date":"2023-11-03","kind":"sale","planned":false,"acquired":false,"shares":143450,"price":2.31,"value":331369.5,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.25 to $2.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":5580077,"source":{"system":"sec-edgar","filing":"0001035443-23-000315","document":"wk-form4_1699307758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000315/wk-form4_1699307758.xml","form_type":"4"}},{"id":1748884,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":2,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":3,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-06T21:56:09.000Z","date":"2023-11-02","kind":"sale","planned":false,"acquired":false,"shares":103808,"price":2.32,"value":240834.56,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.30 to $2.39. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":5723527,"source":{"system":"sec-edgar","filing":"0001035443-23-000315","document":"wk-form4_1699307758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000315/wk-form4_1699307758.xml","form_type":"4"}},{"id":1751533,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-02T20:44:31.000Z","date":"2023-11-01","kind":"sale","planned":false,"acquired":false,"shares":172742,"price":2.36,"value":407671.12,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.32 to $2.46.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":5827335,"source":{"system":"sec-edgar","filing":"0001035443-23-000308","document":"wk-form4_1698957861.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000308/wk-form4_1698957861.xml","form_type":"4"}},{"id":1751532,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-02T20:44:31.000Z","date":"2023-10-31","kind":"sale","planned":false,"acquired":false,"shares":155000,"price":2.41,"value":373550.0,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $2.40 to $2.47.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC, an affiliate of Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":6000077,"source":{"system":"sec-edgar","filing":"0001035443-23-000308","document":"wk-form4_1698957861.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000308/wk-form4_1698957861.xml","form_type":"4"}},{"id":1759988,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2023-10-16T23:17:08.000Z","date":"2023-10-12","kind":"other","planned":false,"acquired":false,"shares":615000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an\naffiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001035443-23-000283","document":"wk-form4_1697498217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000283/wk-form4_1697498217.xml","form_type":"4"}},{"id":1759987,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2023-10-16T23:17:08.000Z","date":"2023-10-12","kind":"other","planned":false,"acquired":true,"shares":615000,"ownership":{"direct":false,"nature":"By subidiary"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an\naffiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":1500000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":615000},"source":{"system":"sec-edgar","filing":"0001035443-23-000283","document":"wk-form4_1697498217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000283/wk-form4_1697498217.xml","form_type":"4"}},{"id":1759986,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-16T23:17:08.000Z","date":"2023-10-12","kind":"other","planned":false,"acquired":false,"shares":1600000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an\naffiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an\naffiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":778977,"source":{"system":"sec-edgar","filing":"0001035443-23-000283","document":"wk-form4_1697498217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000283/wk-form4_1697498217.xml","form_type":"4"}},{"id":1759985,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-16T23:17:08.000Z","date":"2023-10-12","kind":"other","planned":false,"acquired":true,"shares":1600000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an\naffiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an\naffiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":6155077,"source":{"system":"sec-edgar","filing":"0001035443-23-000283","document":"wk-form4_1697498217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544323000283/wk-form4_1697498217.xml","form_type":"4"}},{"id":1822972,"issuer":{"id":111075,"kind":"organization","name":"GreenLight Biosciences Holdings, PBC","symbol":"GRNA"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2023-07-26T20:30:07.000Z","date":"2023-07-24","kind":"other","planned":false,"acquired":false,"shares":1609909,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alexandria Venture Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 24, 2023, SW MergerCo, Inc. (\"Merger Sub\") and SW ParentCo, Inc. (\"Parent\") completed the merger (the \"Merger\") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of May 29, 2023, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, Alexandria Venture Investments, LLC (\"AVI\") contributed all of the shares of Common Stock held by AVI (the \"Rollover Shares\") to Parent in exchange for equity interests of Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 24, 2023, SW MergerCo, Inc. (\"Merger Sub\") and SW ParentCo, Inc. (\"Parent\") completed the merger (the \"Merger\") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of May 29, 2023, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, Alexandria Venture Investments, LLC (\"AVI\") contributed all of the shares of Common Stock held by AVI (the \"Rollover Shares\") to Parent in exchange for equity interests of Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Alexandria Venture Investments, LLC, a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-043416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000120919123043416/doc4.xml","form_type":"4"}},{"id":2219550,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2022-06-29T20:37:37.000Z","date":"2022-06-27","kind":"purchase","acquired":true,"shares":2950000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":2950000,"derivative":{"exercise_price":1,"underlying":"Common Stock","underlying_shares":2950000},"source":{"system":"sec-edgar","filing":"0001035443-22-000176","document":"wf-form4_165653503462000.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000176/wf-form4_165653503462000.xml","form_type":"4"}},{"id":2219549,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant","published_at":"2022-06-29T20:37:37.000Z","date":"2022-06-27","kind":"purchase","acquired":true,"shares":2050000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":2050000,"derivative":{"exercise_price":1,"underlying":"Common Stock","underlying_shares":2050000},"source":{"system":"sec-edgar","filing":"0001035443-22-000176","document":"wf-form4_165653503462000.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000176/wf-form4_165653503462000.xml","form_type":"4"}},{"id":2219548,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-06-29T20:37:37.000Z","date":"2022-06-27","kind":"purchase","acquired":true,"shares":885000,"price":0.9999,"value":884911.5,"ownership":{"direct":false,"nature":"By subidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":885000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":885000},"source":{"system":"sec-edgar","filing":"0001035443-22-000176","document":"wf-form4_165653503462000.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000176/wf-form4_165653503462000.xml","form_type":"4"}},{"id":2219547,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-06-29T20:37:37.000Z","date":"2022-06-27","kind":"purchase","acquired":true,"shares":615000,"price":0.9999,"value":614938.5,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":615000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":615000},"source":{"system":"sec-edgar","filing":"0001035443-22-000176","document":"wf-form4_165653503462000.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000176/wf-form4_165653503462000.xml","form_type":"4"}},{"id":2219546,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-29T20:37:37.000Z","date":"2022-06-27","kind":"purchase","acquired":true,"shares":2065000,"price":1,"value":2065000.0,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":4555077,"source":{"system":"sec-edgar","filing":"0001035443-22-000176","document":"wf-form4_165653503462000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000176/wf-form4_165653503462000.xml","form_type":"4"}},{"id":2219545,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-29T20:37:37.000Z","date":"2022-06-27","kind":"purchase","acquired":true,"shares":1435000,"price":1,"value":1435000.0,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":2378977,"source":{"system":"sec-edgar","filing":"0001035443-22-000176","document":"wf-form4_165653503462000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000176/wf-form4_165653503462000.xml","form_type":"4"}},{"id":2372697,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T21:52:55.000Z","date":"2022-02-23","kind":"other","acquired":false,"shares":300000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by AE7."}],"balance_after":943977,"source":{"system":"sec-edgar","filing":"0001035443-22-000066","document":"wf-form4_164582594767959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000066/wf-form4_164582594767959.xml","form_type":"4"}},{"id":2372696,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T21:52:55.000Z","date":"2022-02-23","kind":"other","acquired":true,"shares":300000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by AVI."}],"balance_after":2490077,"source":{"system":"sec-edgar","filing":"0001035443-22-000066","document":"wf-form4_164582594767959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544322000066/wf-form4_164582594767959.xml","form_type":"4"}},{"id":2437363,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2022-01-11T17:53:24.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":142539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":51398},"source":{"system":"sec-edgar","filing":"0001722024-22-000004","document":"wf-form4_164194159038331.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202422000004/wf-form4_164194159038331.xml","form_type":"4"}},{"id":2437362,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A convertible preferred stock","published_at":"2022-01-11T17:53:24.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":392618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":141575},"source":{"system":"sec-edgar","filing":"0001722024-22-000004","document":"wf-form4_164194159038331.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202422000004/wf-form4_164194159038331.xml","form_type":"4"}},{"id":2437361,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2022-01-11T17:53:24.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":192973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") were convertible at any time at the holder's election and automatically converted on a one-for-2.7732 basis into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."}],"balance_after":192973,"source":{"system":"sec-edgar","filing":"0001722024-22-000004","document":"wf-form4_164194159038331.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202422000004/wf-form4_164194159038331.xml","form_type":"4"}},{"id":2534320,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-10-26T16:51:39.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":1581026,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":166423},"source":{"system":"sec-edgar","filing":"0001722024-21-000012","document":"wf-form4_163528147482023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202421000012/wf-form4_163528147482023.xml","form_type":"4"}},{"id":2534319,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2021-10-26T16:51:39.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":166423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date."}],"balance_after":166423,"source":{"system":"sec-edgar","filing":"0001722024-21-000012","document":"wf-form4_163528147482023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202421000012/wf-form4_163528147482023.xml","form_type":"4"}},{"id":2689192,"issuer":{"id":82741,"kind":"organization","name":"Singular Genomics Systems, Inc.","symbol":"OMIC"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-06-01T17:22:47.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":849301,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":849301},"source":{"system":"sec-edgar","filing":"0001722024-21-000008","document":"wf-form4_162258255031726.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850906/000172202421000008/wf-form4_162258255031726.xml","form_type":"4"}},{"id":2689191,"issuer":{"id":82741,"kind":"organization","name":"Singular Genomics Systems, Inc.","symbol":"OMIC"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A convertible preferred stock","published_at":"2021-06-01T17:22:47.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":1796684,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 26, 2021, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1796684},"source":{"system":"sec-edgar","filing":"0001722024-21-000008","document":"wf-form4_162258255031726.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850906/000172202421000008/wf-form4_162258255031726.xml","form_type":"4"}},{"id":2689190,"issuer":{"id":82741,"kind":"organization","name":"Singular Genomics Systems, Inc.","symbol":"OMIC"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2021-06-01T17:22:47.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":2645985,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2645985,"source":{"system":"sec-edgar","filing":"0001722024-21-000008","document":"wf-form4_162258255031726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850906/000172202421000008/wf-form4_162258255031726.xml","form_type":"4"}},{"id":2846749,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":2,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":3,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T22:17:05.000Z","date":"2021-02-17","kind":"other","acquired":true,"shares":43478,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares have been transferred from AE7 to Alexandria Venture Investments, LLC (\"AVI\") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares have been transferred from AE7 to Alexandria Venture Investments, LLC (\"AVI\") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by AVI."}],"balance_after":2190077,"source":{"system":"sec-edgar","filing":"0001035443-21-000049","document":"wf-form4_161377301066645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544321000049/wf-form4_161377301066645.xml","form_type":"4"}},{"id":2846748,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":2,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":3,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T22:17:05.000Z","date":"2021-02-17","kind":"other","acquired":false,"shares":43478,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares have been transferred from AE7 to Alexandria Venture Investments, LLC (\"AVI\") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares have been transferred from AE7 to Alexandria Venture Investments, LLC (\"AVI\") upon acquisition, an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":1243977,"source":{"system":"sec-edgar","filing":"0001035443-21-000049","document":"wf-form4_161377301066645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544321000049/wf-form4_161377301066645.xml","form_type":"4"}},{"id":2846747,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":2,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":3,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T22:17:05.000Z","date":"2021-02-17","kind":"purchase","acquired":true,"shares":43478,"price":23,"value":999994.0,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc."}],"balance_after":1287455,"source":{"system":"sec-edgar","filing":"0001035443-21-000049","document":"wf-form4_161377301066645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544321000049/wf-form4_161377301066645.xml","form_type":"4"}},{"id":2872379,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-02-10T00:40:23.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":3846152,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":282804},"source":{"system":"sec-edgar","filing":"0001722024-21-000004","document":"wf-form4_161291759833114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000172202421000004/wf-form4_161291759833114.xml","form_type":"4"}},{"id":2872378,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2021-02-10T00:40:23.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":282804,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6-for-one basis, and had no expiration date."}],"balance_after":282804,"source":{"system":"sec-edgar","filing":"0001722024-21-000004","document":"wf-form4_161291759833114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000172202421000004/wf-form4_161291759833114.xml","form_type":"4"}},{"id":2953467,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2020-12-08T21:36:52.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":1168347,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":314664},"source":{"system":"sec-edgar","filing":"0001722024-20-000020","document":"wf-form4_160746339873406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000172202420000020/wf-form4_160746339873406.xml","form_type":"4"}},{"id":2953466,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred stock","published_at":"2020-12-08T21:36:52.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":1428570,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":384748},"source":{"system":"sec-edgar","filing":"0001722024-20-000020","document":"wf-form4_160746339873406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000172202420000020/wf-form4_160746339873406.xml","form_type":"4"}},{"id":2953465,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-12-08T21:36:52.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":699412,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":699412,"source":{"system":"sec-edgar","filing":"0001722024-20-000020","document":"wf-form4_160746339873406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000172202420000020/wf-form4_160746339873406.xml","form_type":"4"}},{"id":3026547,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C convertible preferred stock","published_at":"2020-09-18T19:10:10.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":762961,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":149600},"source":{"system":"sec-edgar","filing":"0001722024-20-000016","document":"wf-form4_160047059351258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1634379/000172202420000016/wf-form4_160047059351258.xml","form_type":"4"}},{"id":3026546,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2020-09-18T19:10:10.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":1107899,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":217235},"source":{"system":"sec-edgar","filing":"0001722024-20-000016","document":"wf-form4_160047059351258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1634379/000172202420000016/wf-form4_160047059351258.xml","form_type":"4"}},{"id":3026545,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A convertible preferred stock","published_at":"2020-09-18T19:10:10.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":4599997,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":901960},"source":{"system":"sec-edgar","filing":"0001722024-20-000016","document":"wf-form4_160047059351258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1634379/000172202420000016/wf-form4_160047059351258.xml","form_type":"4"}},{"id":3026544,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-09-18T19:10:10.000Z","date":"2020-09-18","kind":"purchase","acquired":true,"shares":38461,"price":13,"value":499993.0,"ownership":{"direct":true},"balance_after":1307256,"source":{"system":"sec-edgar","filing":"0001722024-20-000016","document":"wf-form4_160047059351258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1634379/000172202420000016/wf-form4_160047059351258.xml","form_type":"4"}},{"id":3026543,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-09-18T19:10:10.000Z","date":"2020-09-18","kind":"exercise","acquired":true,"shares":1268795,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 5.1 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on September 18, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":1268795,"source":{"system":"sec-edgar","filing":"0001722024-20-000016","document":"wf-form4_160047059351258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1634379/000172202420000016/wf-form4_160047059351258.xml","form_type":"4"}},{"id":3047812,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2020-08-25T22:36:17.000Z","date":"2020-08-25","kind":"exercise","acquired":false,"shares":246305,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":154432},"source":{"system":"sec-edgar","filing":"0001722024-20-000012","document":"wf-form4_159839496225044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000172202420000012/wf-form4_159839496225044.xml","form_type":"4"}},{"id":3047811,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A convertible preferred stock","published_at":"2020-08-25T22:36:17.000Z","date":"2020-08-25","kind":"exercise","acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":313500},"source":{"system":"sec-edgar","filing":"0001722024-20-000012","document":"wf-form4_159839496225044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000172202420000012/wf-form4_159839496225044.xml","form_type":"4"}},{"id":3047810,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-25T22:36:17.000Z","date":"2020-08-25","kind":"exercise","acquired":true,"shares":467932,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":467932,"source":{"system":"sec-edgar","filing":"0001722024-20-000012","document":"wf-form4_159839496225044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000172202420000012/wf-form4_159839496225044.xml","form_type":"4"}},{"id":3079659,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-07-20T22:12:44.000Z","date":"2020-07-20","kind":"exercise","acquired":false,"shares":1651471,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":465082},"source":{"system":"sec-edgar","filing":"0001722024-20-000009","document":"wf-form4_159528299083836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000172202420000009/wf-form4_159528299083836.xml","form_type":"4"}},{"id":3079658,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-20T22:12:44.000Z","date":"2020-07-20","kind":"exercise","acquired":false,"shares":1287128,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":362477},"source":{"system":"sec-edgar","filing":"0001722024-20-000009","document":"wf-form4_159528299083836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000172202420000009/wf-form4_159528299083836.xml","form_type":"4"}},{"id":3079657,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-20T22:12:44.000Z","date":"2020-07-20","kind":"exercise","acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":140806},"source":{"system":"sec-edgar","filing":"0001722024-20-000009","document":"wf-form4_159528299083836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000172202420000009/wf-form4_159528299083836.xml","form_type":"4"}},{"id":3079656,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-20T22:12:44.000Z","date":"2020-07-20","kind":"exercise","acquired":true,"shares":968365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.5509 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on July 16, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":968365,"source":{"system":"sec-edgar","filing":"0001722024-20-000009","document":"wf-form4_159528299083836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000172202420000009/wf-form4_159528299083836.xml","form_type":"4"}},{"id":3108378,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C convertible preferred stock","published_at":"2020-06-16T20:38:43.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":134126,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":63581},"source":{"system":"sec-edgar","filing":"0001722024-20-000005","document":"wf-form4_159233990259960.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1599901/000172202420000005/wf-form4_159233990259960.xml","form_type":"4"}},{"id":3108377,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2020-06-16T20:38:43.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":530616,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":251536},"source":{"system":"sec-edgar","filing":"0001722024-20-000005","document":"wf-form4_159233990259960.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1599901/000172202420000005/wf-form4_159233990259960.xml","form_type":"4"}},{"id":3108376,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A convertible preferred stock","published_at":"2020-06-16T20:38:43.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":395000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":187248},"source":{"system":"sec-edgar","filing":"0001722024-20-000005","document":"wf-form4_159233990259960.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599901/000172202420000005/wf-form4_159233990259960.xml","form_type":"4"}},{"id":3108375,"issuer":{"id":11854,"kind":"organization","name":"Avidity Biosciences, Inc.","symbol":"RNAM"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-06-16T20:38:43.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":502365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 2.1095 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on June 16, 2020, for no additional consideration. The shares had no expiration date."}],"balance_after":502365,"source":{"system":"sec-edgar","filing":"0001722024-20-000005","document":"wf-form4_159233990259960.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599901/000172202420000005/wf-form4_159233990259960.xml","form_type":"4"}},{"id":3191235,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-31T20:38:04.000Z","date":"2020-03-27","kind":"other","acquired":false,"shares":975000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly AE7."}],"balance_after":1243977,"source":{"system":"sec-edgar","filing":"0001035443-20-000079","document":"wf-form4_158568706670079.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544320000079/wf-form4_158568706670079.xml","form_type":"4"}},{"id":3191234,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-31T20:38:04.000Z","date":"2020-03-27","kind":"other","acquired":true,"shares":975000,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares have been transferred from Alexandria Equities No. 7, LLC (\"AE7\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC (\"AVI\"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by AVI."}],"balance_after":2146599,"source":{"system":"sec-edgar","filing":"0001035443-20-000079","document":"wf-form4_158568706670079.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544320000079/wf-form4_158568706670079.xml","form_type":"4"}},{"id":3208900,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T21:03:30.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":287037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":45568},"source":{"system":"sec-edgar","filing":"0000899243-20-008471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008471/doc4.xml","form_type":"4"}},{"id":3208899,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T21:03:30.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":1433240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 16, 2020, the Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 16, 2020, the Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 16, 2020, the Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":227532},"source":{"system":"sec-edgar","filing":"0000899243-20-008471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008471/doc4.xml","form_type":"4"}},{"id":3208898,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T21:03:30.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":125432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19913},"source":{"system":"sec-edgar","filing":"0000899243-20-008471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008471/doc4.xml","form_type":"4"}},{"id":3208897,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:03:30.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":293013,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":293013,"source":{"system":"sec-edgar","filing":"0000899243-20-008471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008471/doc4.xml","form_type":"4"}},{"id":3395022,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-10-09T20:52:08.000Z","date":"2019-10-07","kind":"exercise","acquired":false,"shares":2278345,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":338259},"source":{"system":"sec-edgar","filing":"0001722024-19-000022","document":"wf-form4_157065430537878.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000172202419000022/wf-form4_157065430537878.xml","form_type":"4"}},{"id":3395021,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-10-09T20:52:08.000Z","date":"2019-10-07","kind":"exercise","acquired":false,"shares":4161974,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":617916},"source":{"system":"sec-edgar","filing":"0001722024-19-000022","document":"wf-form4_157065430537878.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000172202419000022/wf-form4_157065430537878.xml","form_type":"4"}},{"id":3395020,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-09T20:52:08.000Z","date":"2019-10-07","kind":"exercise","acquired":true,"shares":956175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 6.7355 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 7, 2019, for no additional consideration. The shares had no expiration date."}],"balance_after":956175,"source":{"system":"sec-edgar","filing":"0001722024-19-000022","document":"wf-form4_157065430537878.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000172202419000022/wf-form4_157065430537878.xml","form_type":"4"}},{"id":3466839,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-07-05T17:13:00.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":165125,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1.2987 shares of common stock upon closing of the Issuer's initial public offering on June 28, 2019, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1.2987 shares of common stock upon closing of the Issuer's initial public offering on June 28, 2019, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214447},"source":{"system":"sec-edgar","filing":"0001722024-19-000017","document":"wf-form4_156236116502296.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202419000017/wf-form4_156236116502296.xml","form_type":"4"}},{"id":3466838,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-05T17:13:00.000Z","date":"2019-07-02","kind":"purchase","acquired":true,"shares":30000,"price":16,"value":480000.0,"ownership":{"direct":true},"balance_after":244447,"source":{"system":"sec-edgar","filing":"0001722024-19-000017","document":"wf-form4_156236116502296.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202419000017/wf-form4_156236116502296.xml","form_type":"4"}},{"id":3466837,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-05T17:13:00.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":214447,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1 share of preferred stock to 1.2987 shares of common stock upon closing of the Issuer's initial public offering on June 28, 2019, for no additional consideration. The shares had no expiration date."}],"balance_after":214447,"source":{"system":"sec-edgar","filing":"0001722024-19-000017","document":"wf-form4_156236116502296.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722024/000172202419000017/wf-form4_156236116502296.xml","form_type":"4"}},{"id":3507120,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B preferred stock","published_at":"2019-05-30T22:12:17.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":772499,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":75318},"source":{"system":"sec-edgar","filing":"0001722024-19-000012","document":"wf-form4_155925432189535.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000172202419000012/wf-form4_155925432189535.xml","form_type":"4"}},{"id":3507119,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A preferred stock","published_at":"2019-05-30T22:12:17.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":3149405,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":307066},"source":{"system":"sec-edgar","filing":"0001722024-19-000012","document":"wf-form4_155925432189535.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000172202419000012/wf-form4_155925432189535.xml","form_type":"4"}},{"id":3507118,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-05-30T22:12:17.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":50000,"price":10,"value":500000.0,"ownership":{"direct":true},"balance_after":432384,"source":{"system":"sec-edgar","filing":"0001722024-19-000012","document":"wf-form4_155925432189535.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000172202419000012/wf-form4_155925432189535.xml","form_type":"4"}},{"id":3507117,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-05-30T22:12:17.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":382384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 10.2564 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on May 28, 2019, for no additional consideration. The shares had no expiration date."}],"balance_after":382384,"source":{"system":"sec-edgar","filing":"0001722024-19-000012","document":"wf-form4_155925432189535.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000172202419000012/wf-form4_155925432189535.xml","form_type":"4"}},{"id":3518895,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-05-21T00:59:26.000Z","date":"2019-05-16","kind":"exercise","acquired":false,"shares":1614860,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Alexandria Venture Investments, LLC (\"AVI\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. (\"ARE\"). Of these shares, 1,243,977 shares are held by AVI as nominee for Alexandria Equities No. 7, LLC (\"AE7\"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc.  AVI disclaims beneficial ownership of the shares held as nominee for AE7."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1614860},"source":{"system":"sec-edgar","filing":"0001035443-19-000142","document":"wf-form4_155840035159502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544319000142/wf-form4_155840035159502.xml","form_type":"4"}},{"id":3518894,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-05-21T00:59:26.000Z","date":"2019-05-16","kind":"exercise","acquired":false,"shares":800716,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Alexandria Venture Investments, LLC (\"AVI\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. (\"ARE\"). Of these shares, 1,243,977 shares are held by AVI as nominee for Alexandria Equities No. 7, LLC (\"AE7\"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc.  AVI disclaims beneficial ownership of the shares held as nominee for AE7."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":800716},"source":{"system":"sec-edgar","filing":"0001035443-19-000142","document":"wf-form4_155840035159502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544319000142/wf-form4_155840035159502.xml","form_type":"4"}},{"id":3518893,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-21T00:59:26.000Z","date":"2019-05-16","kind":"purchase","acquired":true,"shares":975000,"price":10,"value":9750000.0,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by AE7.  Does not include 1,243,977 shares held directly by AVI as nominee for AE7, as described in footnote (2), which shares may be deemed to be beneficially owned by AE7."}],"balance_after":975000,"source":{"system":"sec-edgar","filing":"0001035443-19-000142","document":"wf-form4_155840035159502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544319000142/wf-form4_155840035159502.xml","form_type":"4"}},{"id":3518892,"issuer":{"id":67708,"kind":"organization","name":"Applied Therapeutics, Inc.","symbol":"APLT"},"owners":[{"id":419,"kind":"organization","name":"ALEXANDRIA REAL ESTATE EQUITIES, INC.","symbol":"ARE","position":1,"cik":"0001035443","reported_name":"ALEXANDRIA REAL ESTATE EQUITIES INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":2,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90214,"kind":"organization","name":"Alexandria Equities No. 7, LLC","position":3,"cik":"0001776437","reported_name":"Alexandria Equities No. 7, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-21T00:59:26.000Z","date":"2019-05-16","kind":"exercise","acquired":true,"shares":2415576,"ownership":{"direct":false,"nature":"By subsidiary"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Alexandria Venture Investments, LLC (\"AVI\"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. (\"ARE\"). Of these shares, 1,243,977 shares are held by AVI as nominee for Alexandria Equities No. 7, LLC (\"AE7\"), another wholly owned subsidiary of Alexandria Real Estate Equities, Inc.  AVI disclaims beneficial ownership of the shares held as nominee for AE7."}],"balance_after":2415576,"source":{"system":"sec-edgar","filing":"0001035443-19-000142","document":"wf-form4_155840035159502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035443/000103544319000142/wf-form4_155840035159502.xml","form_type":"4"}},{"id":3529089,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2019-05-13T23:49:34.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":628931,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78285},"source":{"system":"sec-edgar","filing":"0001722024-19-000008","document":"wf-form4_155779135873390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000172202419000008/wf-form4_155779135873390.xml","form_type":"4"}},{"id":3529088,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2019-05-13T23:49:34.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":365727,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":45523},"source":{"system":"sec-edgar","filing":"0001722024-19-000008","document":"wf-form4_155779135873390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000172202419000008/wf-form4_155779135873390.xml","form_type":"4"}},{"id":3529087,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2019-05-13T23:49:34.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":372500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":46366},"source":{"system":"sec-edgar","filing":"0001722024-19-000008","document":"wf-form4_155779135873390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000172202419000008/wf-form4_155779135873390.xml","form_type":"4"}},{"id":3529086,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2019-05-13T23:49:34.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":223500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":27819},"source":{"system":"sec-edgar","filing":"0001722024-19-000008","document":"wf-form4_155779135873390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000172202419000008/wf-form4_155779135873390.xml","form_type":"4"}},{"id":3529085,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T23:49:34.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":197993,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock was convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The shares had no expiration date."}],"balance_after":197993,"source":{"system":"sec-edgar","filing":"0001722024-19-000008","document":"wf-form4_155779135873390.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000172202419000008/wf-form4_155779135873390.xml","form_type":"4"}},{"id":3856619,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2018-08-01T17:47:19.000Z","date":"2018-07-30","kind":"other","acquired":true,"shares":27945,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock.  The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock.  The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants."}],"balance_after":27945,"derivative":{"exercise_price":0.01,"exercise_date":"2017-02-17","expiration_date":"2026-12-31","underlying":"Common stock","underlying_shares":27945},"source":{"system":"sec-edgar","filing":"0001722024-18-000014","document":"wf-form4_153316002374602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1330436/000172202418000014/wf-form4_153316002374602.xml","form_type":"4"}},{"id":3856618,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase Series D preferred stock","published_at":"2018-08-01T17:47:19.000Z","date":"2018-07-30","kind":"other","acquired":false,"shares":470254,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock.  The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock.  The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Issuer's initial public offering and without payment of further consideration, the warrants to purchase Series D preferred stock automatically converted into warrants to purchase the Issuer's common stock.  The transaction is listed solely for the purpose of reporting the change in the title and amount of securities underlying the warrants."}],"balance_after":0,"derivative":{"exercise_date":"2017-02-17","expiration_date":"2026-12-31","underlying":"Series D preferred stock","underlying_shares":470254},"source":{"system":"sec-edgar","filing":"0001722024-18-000014","document":"wf-form4_153316002374602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1330436/000172202418000014/wf-form4_153316002374602.xml","form_type":"4"}},{"id":3856617,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D preferred stock","published_at":"2018-08-01T17:47:19.000Z","date":"2018-07-30","kind":"exercise","acquired":false,"shares":4371889,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":259808},"source":{"system":"sec-edgar","filing":"0001722024-18-000014","document":"wf-form4_153316002374602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1330436/000172202418000014/wf-form4_153316002374602.xml","form_type":"4"}},{"id":3856616,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2018-08-01T17:47:19.000Z","date":"2018-07-30","kind":"purchase","acquired":true,"shares":136364,"price":11,"value":1500004.0,"ownership":{"direct":true},"balance_after":396172,"source":{"system":"sec-edgar","filing":"0001722024-18-000014","document":"wf-form4_153316002374602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1330436/000172202418000014/wf-form4_153316002374602.xml","form_type":"4"}},{"id":3856615,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2018-08-01T17:47:19.000Z","date":"2018-07-30","kind":"exercise","acquired":true,"shares":259808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on a 0.0594-for-1 basis immediately prior the closing of the Issuer's initial public offering."}],"balance_after":259808,"source":{"system":"sec-edgar","filing":"0001722024-18-000014","document":"wf-form4_153316002374602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1330436/000172202418000014/wf-form4_153316002374602.xml","form_type":"4"}},{"id":3862708,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F convertible preferred stock","published_at":"2018-07-23T16:54:27.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":90837},"source":{"system":"sec-edgar","filing":"0001722024-18-000010","document":"wf-form4_153237924971194.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000172202418000010/wf-form4_153237924971194.xml","form_type":"4"}},{"id":3862707,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-1 convertible preferred stock","published_at":"2018-07-23T16:54:27.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":285714,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":25952},"source":{"system":"sec-edgar","filing":"0001722024-18-000010","document":"wf-form4_153237924971194.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000172202418000010/wf-form4_153237924971194.xml","form_type":"4"}},{"id":3862706,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E convertible preferred stock","published_at":"2018-07-23T16:54:27.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":111111,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series E preferred stock was convertible into the Issuer's common stock at a ratio of 8.5626 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series E preferred stock was convertible into the Issuer's common stock at a ratio of 8.5626 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":12976},"source":{"system":"sec-edgar","filing":"0001722024-18-000010","document":"wf-form4_153237924971194.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000172202418000010/wf-form4_153237924971194.xml","form_type":"4"}},{"id":3862705,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D convertible preferred stock","published_at":"2018-07-23T16:54:27.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":10454,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":949},"source":{"system":"sec-edgar","filing":"0001722024-18-000010","document":"wf-form4_153237924971194.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000172202418000010/wf-form4_153237924971194.xml","form_type":"4"}},{"id":3862704,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2018-07-23T16:54:27.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":208333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":18923},"source":{"system":"sec-edgar","filing":"0001722024-18-000010","document":"wf-form4_153237924971194.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000172202418000010/wf-form4_153237924971194.xml","form_type":"4"}},{"id":3862703,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2018-07-23T16:54:27.000Z","date":"2018-07-23","kind":"purchase","acquired":true,"shares":66667,"price":15,"value":1000005.0,"ownership":{"direct":true},"balance_after":216304,"source":{"system":"sec-edgar","filing":"0001722024-18-000010","document":"wf-form4_153237924971194.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000172202418000010/wf-form4_153237924971194.xml","form_type":"4"}},{"id":3862702,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2018-07-23T16:54:27.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":149637,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series E preferred stock was convertible into the Issuer's common stock at a ratio of 8.5626 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":149637,"source":{"system":"sec-edgar","filing":"0001722024-18-000010","document":"wf-form4_153237924971194.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000172202418000010/wf-form4_153237924971194.xml","form_type":"4"}},{"id":3924144,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C preferred stock","published_at":"2018-05-21T16:48:38.000Z","date":"2018-05-11","kind":"exercise","acquired":false,"shares":619195,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":151801},"source":{"system":"sec-edgar","filing":"0001722024-18-000006","document":"wf-form4_152693569978430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000172202418000006/wf-form4_152693569978430.xml","form_type":"4"}},{"id":3924143,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B preferred stock","published_at":"2018-05-21T16:48:38.000Z","date":"2018-05-11","kind":"exercise","acquired":false,"shares":1388889,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":340497},"source":{"system":"sec-edgar","filing":"0001722024-18-000006","document":"wf-form4_152693569978430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000172202418000006/wf-form4_152693569978430.xml","form_type":"4"}},{"id":3924142,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 preferred stock","published_at":"2018-05-21T16:48:38.000Z","date":"2018-05-11","kind":"exercise","acquired":false,"shares":416650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":102145},"source":{"system":"sec-edgar","filing":"0001722024-18-000006","document":"wf-form4_152693569978430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000172202418000006/wf-form4_152693569978430.xml","form_type":"4"}},{"id":3924141,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-21T16:48:38.000Z","date":"2018-05-11","kind":"exercise","acquired":true,"shares":594443,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-3, Series B and Series C preferred stock was convertible into the Issuer's common stock at a ratio of 4.079 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering.  The shares had no expiration date."}],"balance_after":594443,"source":{"system":"sec-edgar","filing":"0001722024-18-000006","document":"wf-form4_152693569978430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000172202418000006/wf-form4_152693569978430.xml","form_type":"4"}},{"id":4155928,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D convertible preferred stock","published_at":"2017-11-20T15:01:01.000Z","date":"2017-11-15","kind":"exercise","acquired":false,"shares":770249,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable"}],"balance_after":0,"derivative":{"exercise_date":"2017-04-24","underlying":"Common stock","underlying_shares":225680},"source":{"system":"sec-edgar","filing":"0001722024-17-000004","document":"wf-form4_151119004239433.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000172202417000004/wf-form4_151119004239433.xml","form_type":"4"}},{"id":4155927,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":90213,"kind":"organization","name":"Alexandria Venture Investments, LLC","position":1,"cik":"0001722024","reported_name":"Alexandria Venture Investments, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2017-11-20T15:01:01.000Z","date":"2017-11-15","kind":"exercise","acquired":true,"shares":225680,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock"}],"balance_after":225680,"source":{"system":"sec-edgar","filing":"0001722024-17-000004","document":"wf-form4_151119004239433.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000172202417000004/wf-form4_151119004239433.xml","form_type":"4"}}]}